SCIENION AG, a leading provider of ultra-low volume precision liquid handling systems, and Greiner Bio-One, a leading manufacturer of synthetic materials for health services and a pioneer of new medical technology, today announced that they have entered into an agreement to co-develop advanced tests and integrated solutions for rapid and multiplexed diagnostics.
Berlin, Germany, and Kremsmünster, Austria, November 13, 2015: The emerging field of rapid diagnostic tests is becoming increasingly important in a variety of applications. For infectious diseases, the time to diagnosis is a critical factor for ensuring successful management. This collaboration will focus on the development of new tests that will optimize patient care by providing sensitive and accurate test results within only 75 minutes. The collaboration will bring together SCIENION’s core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing with Greiner Bio-One’s innovative Genspeed® testing system.
Dr. Holger Eickhoff, CEO of SCIENION AG, states: "We believe combining our expertise and sciFLEXARRAYER technology with Greiner Bio-One’s Genspeed® platform may enable us to bring personalized healthcare to the next level. We look forward to collaborating with Greiner Bio-One on this exciting development to optimize treatment outcomes for patients."
"We are looking forward to this collaboration to address the significant market need in the detection of human pathogens utilizing our Genspeed® platform", said Dr. Max Sonnleitner, Head of Rapid Testing Technologies/ Business Development at Greiner Bio-One Diagnostics. "Similar to our Genspeed® MRSA testing system, all jointly developed future tests have the potential to become very successful on the market".
Visit us at MEDICA 2015, November 16 – 19, 2015 in Düsseldorf, Germany. Please visit us at booth A42 in hall 3.

About Greiner Bio-One International GmbH
Greiner Bio-One specializes in the development, production and distribution of quality plastic products for laboratory use. The company is a technology partner for hospitals, laboratories, universities, research institutes, the diagnostic and pharmaceutical industry, and the biotechnology industry. Greiner Bio-One is split into four divisions: Preanalytics, BioScience, Diagnostics and OEM. Greiner Bio-One International GmbH generated sales of EUR 388 million in 2014 and has 1800 employees, 23 subsidiaries and numerous distribution partners in more than 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).
Greiner Bio-One GmbH – Diagnostics Division
The division has four strategic focuses in the field of diagnostics: Screening test procedures for sexually transmitted diseases, hospital acquired infections, vaccine safety, and customer-specific products. Two completely different detection systems satisfy mass analysis (screening) requirements, as well as individual analysis requirements for acute medicine.
About SCIENION
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
Greiner Bio-One GmbH
Peter Föttinger
Bad Haller Straße 32
4550 Kremsmünster
Phone +43 (0)7583 6791
Fax +43 (0)7583 6318[email protected]www.gbo.com
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone +49 (0)30 – 6392 1700
Fax +49 (0)30 – 6392 1701[email protected]www.scienion.com

British medical device developer QuantuMDx (QMDx) and German life sciences company SCIENION have partnered to take QMDx’s highly multiplexed nanowire array to market. This biosensor is a component of QMDx’s flagship product Q-POC™, a handheld molecular diagnostic device that will provide results in 15 minutes for a few pounds at the patient’s side.
Newcastle-Upon-Tyne, England and Berlin, Germany, June 9, 2015: QMDx utilises SCIENION’s proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx’s novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.
The companies’ longstanding relationship was cemented with QMDx’s purchase of SCIENION’s sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterisation from R&D to mass manufacture.
The instrument is the newest fixture in QMDx’s chemistry facility at the University of Newcastle upon Tyne’s Chemical Nanoscience Laboratories.
QMDx’s Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx’s R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."
"We’re thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."
Please visit us at:
BIO International Convention 2015, June 15 – 18, 2015; Philadelphia, PA, USA. SCIENION at booth 1013-01 (part of the Berlin-Brandenburg booth)
QuantuMDx at booth 1127
 
About QuantuMDx Group
QuantuMDx Group is a multinational medical device developer headquartered in the United Kingdom, with subsidiary operations in the United States and Singapore. Expected for commercialisation in 2016, the company’s flagship product Q-POC™ will empower overburdened healthcare systems worldwide with gold standard molecular diagnostics at a fraction of the cost of traditional testing. Q-POC’s superior multiplexing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’. By geotagging and networking this disease data, QuantuMDx will build a real-time global pathogen monitoring system called the Internet of Life™. QuantuMDx was co-founded by CEO Elaine Warburton OBE, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee. QuantuMDx has received grants from the UK and EU governments, and partnered with FIND in 2014.
About SCIENION
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.
 
Contact
QuantuMDx Group Ltd
Lucy Harvey
Business Development and Marketing Officer, QuantuMDx Group Ltd
Phone 0870 803 1234[email protected] 
SCIENION AG
Almut Gebhard
Volmerstr. 7b
D-12489 Berlin
Phone +49 (0)30 – 6392 1700
Fax +49 (0)30 – 6392 1701 [email protected]http://www.scienion.com/

SCIENION AG and GENOMICA S.A.U today announced the launch of multiplex CE-IVD tests for sexually transmitted infections (STIs), CLART^® STI A&B.

Berlin, Germany, and Madrid, Spain, October 29, 2014: According to recent estimates, the global incidence rate for curable STI infections per year, such as those with Treponema pallidum (Syphilis), Neisseria gonorrhoea (Gonorrhea), Chlamydia trachomatis and Trichomonas vaginalis (Trichomoniasis), is about 340 million cases. Aside from implications for patients, that may depend on treatment protocols established by the different countries, these infections and their after-effects represent an enormous burden for healthcare and economic systems worldwide.

Reliable, efficient and unified diagnostic tools are essential for the control and prevention of STIs.  With such a goal GENOMICA and SCIENION have jointly developed a novel multiplex test that combines both companies’ expertise and technologies. SCIENION contributes its proprietary sciFLEXARRAYER non-contact printing technology and consumables, such as sciPLEXPLATES, while GENOMICA applies that technology, combining it with a multiplex PCR, CLART^® Technology, allowing the simultaneous detection of bacteria, virus, fungi and parasites on a Low Density Microarray format.

CLART^® STIs A&B is a combination of two different detection panels. It provides the end-user with the opportunity to rapidly detect therapy-susceptible or symptomatic pathogens, thus avoiding a potential exponential retransmission into the general population. This CLART^® STIs A&B kit, together with the employed microtiter plate format, was validated in cooperation with reference laboratories, university hospitals and family planning clinics.  Sensitivity and specificity values of circa 94% and 99% respectively were obtained, with exception of Mycoplasma genitalium, which shows a reduced sensitivity and specificity in swabs samples (86% and 89% respectively). The kit is now a CE-IVD product (CE NB0318).

Dr. Rosario Cospedal, CEO of GENOMICA S.A.U, stated: “We are very happy to launch our new IVD test kit for the detection of STIs based on our partnership with SCIENION. Our strategic cooperation proved once again successful as the technologies of our companies optimally complement one another. This gives us a competitive advantage in the molecular diagnostics market and CLART^® STIs A&B has the potential to become a benchmark in clinical STI diagnosis.”

Dr. Holger Eickhoff, CEO of SCIENION AG, added: “According to a recent publication of the WHO, sexually transmitted infections and the high morbidity associated with STIs remain an important focus area for global public health. Joint efforts of different players are necessary to control the expansion of these diseases.  We are happy to contribute to this goal with easy-to-use, cost-effective and reliable in vitro diagnostics as developed together with GENOMICA.”

The existing collaboration between SCIENION and GENOMICA aims at accelerating the development of better and safer in vitro diagnostics. The companies jointly seek to offer new services for customers in the microarrays life science industry. These services range from assay development to manufacturing of microarrays individually tailored to the needs and specifications of customers.

Please, visit our joint booth at MEDICA 2014, Nov. 12-15, Düsseldorf, Hall 3 / booth 3A42

About GENOMICA
GENOMICA S.A.U. develops, produces and commercializes in vitro diagnostic products as well as services for genetic identification. During the last 22 years, the company has been a pioneer in molecular diagnostic tools using the multiplexing PCR technique as the basis of a sensitive, specific and robust assay. GENOMICA holds all the certifications and accreditations necessary to ensure the highest quality standards of its products and services from R&D to the market. The development of its own diagnostic platform CLART^® (Clinical Array Technology), combined with a high production capacity and protocols automation, has allowed the company to achieve a very successful internationalization process, being nowadays present in 40 countries around the world.
GENOMICA has developed diagnostic tests for Human Papillomavirus, respiratory viruses, Herpes virus, Enterovirus, microorganisms causing Sepsis and Gastroenteritis. With the launch of the new kit line (CLART^® CMA) for the detection of somatic mutations involved in tumor response to therapy, GENOMICA has entered into the field of medical oncology and personalized medicine. For more information visit www.genomica.com.

About SCIENION
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone +49 (0)30 – 6392 1700
Fax +49 (0)30 – 6392 1701[email protected]www.scienion.com

GENOMICA S.A.U.
Juan Bataller
Alcarria, 7
Pol. Industrial de Coslada, Coslada
28823 Madrid
Phone +34 91 674 89 90
Fax +34 91 674 89 91 [email protected] www.genomica.com

SCIENION AG, The Institute for Global Food Security (IGFS) at Queen’s University Belfast and MBio Diagnostics today announced that IGFS are using SCIENION technology for the manufacturing of portable immunoassay cartridges.
Professor Chris Elliott’s group at IGFS is currently using sciFLEXARRAYER technology to produce arrays in cartridges for the multiplexed detection of marine toxins utilizing the MBio portable SnapEsi® assay platform.

Berlin, Germany, Belfast, Northern Ireland, and Boulder, CO, USA, October 8, 2014: Marine toxins can have serious implications for both public health and the economy. As a result, routine monitoring for a number of recognized marine toxins in edible shellfish is a regulatory requirement in many areas worldwide. Animal-based assays have historically been used to indicate sample toxicity thus helping to ensure consumer safety. Ethical issues surround the use of these tests and sample analysis requires marine samples to be returned to land for analysis in specialized laboratories. In recent years there has been an increased focus on developing and adopting non animal-based methods. Moreover, approaches that could allow samples to be tested at sea are desirable because it could reduce the economic impact of returning contaminated produce to shore. MBio’s SnapEsi® System enables a solution that is an alternative to the animal-based tests. Its array format allows for multiplexed screening for targeted toxins whilst its small footprint facilitates operation outside of a conventional laboratory setup.

IGFS is using the sciFLEXARRAYER technology to spot some of their key reagents that allows them to run competitive immunoassays. “The sciFLEXARRAYER S5 gives superb accuracy, not only in terms of spot location but also volume. This really helps minimize assay %CV.” says Dr Terry McGrath of IGFS. “SCIENION has been very supportive. Their initial training was fantastic and they had a refresher session a few weeks later. This was great because it allowed us to get to know the instrument and come up with questions directly related to our needs.”

About IGFS
The Institute for Global Food Security is based at Queen’s University Belfast within the School of Biological Sciences. The Institute houses a suite of state-of-the-art laboratories, conducting cutting edge research into various topics ranging from soil & plant health through to food security. Since the inception of the UK’s first Institute of Agri-Food and Land Use in 2006, the work of the Institute has become internationally-recognized for its excellence in research and teaching.  Over time the Institute has focused even more intently on its core founding principles, resulting in rebranding to become the Institute for Global Food Security. The Institute for Global Food Security will be a key partner in national and global efforts to provide the world’s growing population with a sustainable, safe and secure supply of high quality food.   

About MBio Diagnostics
MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held diagnostics and life sciences company based in Boulder, CO, USA. The MBio Diagnostics platform delivers laboratory quality, multiplexed biological assays in a device format that combines speed, simplicity, and portability.  MBio is developing technologies for human in vitro diagnostics, food, environmental, and industrial applications.

About SCIENION AG
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by their versatility, precision and robustness. The company is renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701mailto: [email protected]http://www.scienion.com

Institute for Global Food Security
Queen’s University Belfast
Terry McGrath
18-30 Malone Road
Belfast, BT9 5BN
Phone: +44 (0) 28 90976514
Fax: +44 (0) 28 90976513mailto: [email protected]http://www.qub.ac.uk/research-centres/InstituteforGlobalFoodSecurity

MBio Diagnostics, Inc
Chris Myatt
5603 Arapahoe Avenue, Suite 1
Boulder, CO 80303
USA
Phone: 303-952-2815mailto: [email protected]http://mbiodx.com

The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Vienna/Brno/Berlin – September 24, 2014: Colon cancer is one of the most common cancers being the second most common cause of cancer in women and the third most common in men. At the same time colon cancer is the fourth common cause of cancer related death. Early detection of this disease increases both the therapeutic success and the chance of survival. Current diagnostic practice involves either uncomfortable invasive procedures or uses stool tests, the latter resulting in a high percentage of false-positive results. The collaboration between BioVendor, SCIENION and AIT aims to use biomarkers for the early detection and screening based on patients blood samples. In the project, AIT’s proprietary biomarkers will be developed into an easy-to-use in-vitro diagnostic (IVD) test kit. The technology takes advantage of the fact that specific tumor autoantibodies can be detected in blood of cancer patients in a very early stage of tumor development.
Development of an in vitro test kit
The three companies will work closely together to develop the in-vitro diagnostic test for the global market. AIT provides their previously identified and patented biomarkers, specific for blood-based diagnosis of colon cancer. BioVendor, represented by its subsidiary company TestLine Clinical Diagnostics, will bring in its development expertise and distribution network. SCIENION contributes with its longstanding expertise in the microarray market and will be responsible for assay development and manufacturing using the company’s high-quality microtiter plates (sciPLEXPLATES).
Martin Weber, Head of the business unit Molecular Diagnostics at AIT, said: "We are entering the cooperation with BioVendor and Scienion extremely enthusiastic and we strongly believe that the newly formed consortium has the power to perfectly drive forward AITs breakthrough biomarker technologies into market-ready solutions."
"We share the excitement expressed by Martin. Early, cost-efficient and non-invasive diagnosis of colon cancer is a largely unmet medical need that presents the newly formed consortium with an attractive commercial opportunity", said Viktor Ružička, CEO of the BioVendor group.
Holger Eickhoff, CEO of SCIENION AG, commented: "We are very happy to expand our existing collaboration with BioVendor for this new project. Getting AIT with its proprietary biomarker panel on board as a third partner is the perfect match for the development of colon cancer IVD. Once established, our test kit has the potential for broad colon cancer screening applications."
About the AIT Austrian Institute of Technology
The AIT is Austria’s largest non-university research institute and is, among European research institutes, a specialist in key infrastructure issues. The Molecular Diagnostics business unit focusses on biomarkers, assay development, bioinformatics and diagnostic biosensors and has several patents on biomarkers for cancer. The group combines innovative high throughput technologies with their own in-house workflow-based data analysis tools to support partners and customers in the ultimate goal of defining biomarkers for personalized medicine and early disease detection.
About BioVendor
BioVendor is a developer and manufacturer of high-quality immunoassays, recombinant proteins, and antibodies. TestLine Clinical Diagnostics s.r.o. established in 1993, specializes in development, production and distribution of in vitro diagnostic kits for human and veterinary medicine. It is one of the most important producers and suppliers of diagnostic kits in the field of serology in the Czech Republic. Our products are routinely used throughout 40 countries around the world.
About SCIENION
SCIENION is a leading supplier of quality instrumentation and services for low volume liquid handling. Proprietary technologies include piezo electric dispensing, surface modifications and microarray manufacturing. Based on SCIENION’s core competencies in ultra-low volume liquid dispensing, assay miniaturization, and microarray manufacturing, the company provides an integrated product portfolio facilitating a number of applications: multiplex assays, DNA microarray production, biosensor loading, miniaturized PCR, peptide microarrays, protein microarrays, cell deposition.
Contact
Dr. Martin Weber
Donau-City-Straße 1
1220 Wien
Phone: 050550 4420
Fax: +: 050550 4450mailto:[email protected]http://www.ait.ac.at BioVendor Laboratorni medicina a.s.
Dr. Viktor Růžička
Karasek 1767/1
621 00 Brno
Czech Republic
Phone: +420-549 124 185
Fax: +420-549 211 460 mailto:[email protected]http://www.biovendor.com SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701 mailto:[email protected]http://www.scienion.com/

SCIENION AG today announced that the company supports the unique research project ‘Rheines Wasser’ involving a 1,231 km long Rhine marathon swim. SCIENIONs contribution include water quality testing with a novel multi-parameter microarray, financing all microarrays, sample preparation, experimental work and providing equipment.

Dortmund and Berlin, Germany, August 20, 2014: In the ambitious project ‘Rheines Wasser’, Andreas Fath, a Furtwangen University professor of Physical and Analytical Chemistry specializing in Ecological Engineering, plans to swim the Rhine from the source in the Swiss Alps to the estuary in the North Sea. Beside the sporting challenge, Fath and his team will take daily water samples all along the route which will be tested for industrial chemicals, hormones, anti-depressants, sweeteners, antibiotics, painkillers, drugs, pathogens and microplastics, among other substances. The event also aims to use the high level of public interest to raise awareness for the importance of water as a resource and the need for increased water protection.

SCIENION and other partners contribute with different methods of testing the water quality. SCIENION uses a novel microarray that is capable of detecting up to 150 microorganisms simultaneously. Testing includes waterborne pathogens and toxic algae as well as select bioindicators such as certain diatoms. The prototype of this chip had been developed with partners in the microAqua EU research project. Dr. Holger Eickhoff, CEO of SCIENION AG, states: “We are very enthusiastic to take part in this exceptional project. ‘Rheines Wasser’ represents a first field study for our new microarray and I am excited about the results reflecting the allocation of microorganisms along the river Rhine. It will be also interesting to see if and how our results correlate with other methods of water quality testing employed in this project.” After this field study SCIENION plans to market the microarray as a rapid, inexpensive and efficient test enabling monitoring surface water quality and biohazard detection in water.

However, SCIENION’s commitment has not been limited to providing scientific experiments and equipment. After tracking the progress of Andreas Fath covering the distance since his swim start on July 28 in the media and on the project website SCIENION decided to visit the team at the interim destination Bonn on August 15. Eickhoff comments: “It is unbelievable what Andreas and his team get realized. I just wanted to experience the atmosphere and ongoing experiments on site.” Being a trained swimmer himself, Eickhoff furthermore joined Andreas Fath in swimming the last 10 km to Bonn. Andreas Fath stated: “I enjoyed swimming with Holger. If the results of the µAqua test are as good as his swimming, it will become a big commercial success.”

For more information see http://www.rheines-wasser.eu and the recent press release (German only) of the project.

About SCIENION AG
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by their versatility, precision and robustness. The company is renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701[email protected]www.scienion.com

SCIENION AG today announced that Ostendum R&D B.V., a Dutch company focused on the development and production of fast, highly sensitive, portable, easy-to-use and cost-effective biosensors, is using SCIENION’s sciFLEXARRAYER to print their unique Lab-on-a-Chip nanodevices.
Dortmund and Berlin, Germany, January 27, 2014: Ostendum has developed a proprietary technology for the Lab-on-chip nanodevices market which has been awarded a number of awards, most recently the 2013 Frost & Sullivan Award for Technology Innovation Leadership. The technology includes both novel Lab-on-a-Chip nanodevices and an integral optical detection platform.
"We were able to experience and see the advantages of SCIENION’s sciFLEXARRAYER technology at the laboratory of Dr. Aart van Amerongen of the Biomolecular Sensing & Diagnostics group of Wageningen UR (collaborative group conducting food research as a core area)", says Ostendum’s CEO Dr. Paul H. J. Nederkoorn. "We came to the conclusion that the sciFLEXARRAYER non-contact dispenser would be the best solution to precisely and accurately spot antibodies onto our nanodevices. After further test runs with excellent results in SCIENION’s facilities, we opted for the SX model which enables us to complete any R&D processes and to scale up for production. This compact and fully-automated system will allow high throughput production of our chips. Furthermore it is suitable for our future activities in developing higher multiplexed chips, whereas we may increase the number of channels from currently four to up to eight channels per device."
Dr. Holger Eickhoff, CEO of SCIENION AG, states: "With its fully portable Lab-on-a-Chip system Ostendum has developed a unique technology which offers tailor-made solutions for present needs in healthcare diagnostics as well as other areas such as food and water analytics or biological warfare testing. This portable point-of-care diagnostics technology for viruses and bacteria may play an important role in future control of epidemics or biohazards. Furthermore, point-of-care diagnostics of biomarkers will enable healthcare providers with vital information to act quickly and adequately. We are very happy that Ostendum decided for the sciFLEXARRAYER SX to produce their LOC nanodevices. I am looking forward to a productive collaboration with this innovative company." The potential of Ostendum’s technology for changing the healthcare landscape is also reflected by recent investments of two Dutch health insurers. In May 2013, the company raised venture capital from Achmea, the largest health insurer of the Netherlands, and from de Friesland Zorgverzekeraar.
Please meet us at: Molecular Med TRI-CON, February 10-12, 2014 in San Francisco, CA, USA; booth 522. Register now for the 1st Sony DADC & SCIENION Symposium "Ideas at the point of commercialization", March 31, 2014 in Salzburg, Austria. The agenda is available at www.scienion.com.

About Ostendum
Ostendum is a group of companies that commercializes Lab-on-a-Chip optical biosensing nanodevices for detection of micro-organisms, biomarkers, (bio-) molecules and nano-particles. Ostendum develops and produces both the necessary hardware and software, including its own Lab-on-a-Chip system. Ostendum’s Lab-on-a-Chip interferometric nanotechnology is unique, being completely label-free, and extremely sensitive, being at least 100 times more sensitive than all currently available competing detection methods. The LOC devices do not only enable the detection of bacteria, viruses, yeasts, proteins and DNA molecules but also the determination of its concentration. Tests can be performed within minutes and everywhere, due to the portability of the system, contributing to faster analysis and savings on operational costs.

About SCIENION AG
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by their versatility, precision and robustness. The company is renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
[email protected]www.scienion.com

Ostendum R&D B.V.
Dr. Paul H. J. Nederkoorn
De Veldmaat 10 Bldg. 46 / HTF-SEPA HI.222-224
P.O. Box 217
NL-7500 AE Enschede
The Netherlands
Tel. +31 (0)53 20 30 063
[email protected] www.ostendum.com 

SCIENION AG today announced that AVS, a professional society dedicated to the science and technology of materials, interfaces and processing, has awarded SCIENION’s sciFLEXARRAYER dispenser with a Product Technology Innovation Award. Candidates for the award had been selected at the AVS 60^th International Symposium and Exhibition in Long Beach CA, USA, October 28-31, 2013.
Dortmund and Berlin, Germany, November 21, 2013: AVS is the premier Materials Science Society where new developments in the field are presented every year. This award recognizes and encourages outstanding innovation in the fields of interest to AVS. The award comes along with a write up in the January Issue of Physics Today, the flagship publication of the American Institute of Physics (AIP), as well as peer recognition of the innovation SCIENION brings to the field of material science.
SCIENION technology enables high-throughput experimentation in a scientific discipline where such experiments had been previously difficult to achieve. Accurate and precise delivery of various monomer combinations allows for the creation of high quality polymeric surfaces with unprecedented features, such as component gradients, or high density arrays of functionally diverse features. In addition, the flexibility of the dispensing technology also enables overlays with cell lines or precious native proteins. “We feel deeply honored to receive this prestigious AVS award for our sciFLEXARRAYER technology” says Dr. Holger Eickhoff, CEO of SCIENION AG. “This marks only the beginning of our entry into the field of materials science. Exciting new developments will be introduced in 2014.”

About AVS
As an interdisciplinary, professional society, AVS supports networking among academic, industrial, government, and consulting professionals involved in a variety of disciplines – chemistry, physics, biology, mathematics, all engineering disciplines, business, sales, etc. through common interests related to the basic science, technology development, and commercialization of materials, interfaces, and processing area.
Founded in 1953 with a focus on high vacuum technology (leading to the name American Vacuum Society), today AVS is organized into 10 technical divisions and 2 technical groups that encompass a range of established as well as emerging science and technology areas.
For more information see http://www.avs.org.

About SCIENION AG
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by their versatility, precision and robustness. The company is renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in New Jersey, USA.

Contact
SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone: +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
[email protected]www.scienion.com